It’s no secret that China has become an ever-increasing component for drug development, and their pharmaceutical market value proves just that.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Novartis’ entry into the digital technology market intensifies with the recent launch of its mobile-phone based app to help collect data from eye disease studies.
AI genomics company Freenome has announced a partnership with proteomics company Biognosys, to enhance its broad-signal approach to early-cancer detection and precision oncology.
It’s been a busy time for R&D execs, as they continue to be snapped up by rival pharma companies, proving that it’s a competitive time out there at the top.
Illumina’s new Bay Area campus boasts connectivity, collaboration, and innovation, but some are unsure whether it will be able to draw in the appeal from workers.
Allergan has retracted its interest in pursuing a deal for Shire, only a mere few hours after originally saying so.
BD Bioscience today launched a new cloud-based system called ‘BD Synapsys Microbiology Informatics Solution’ to facilitate faster diagnostic results and improve infectious disease management.
CMO and Senior VP of Global Medical at Amgen, John Tsai, MD, is moving to Novartis to act as their new CMO and Head of Global Drug Development (GDD).
Amazon has revealed that it’s pulling out of its move to enter the pharmaceutical distribution market, despite only announcing the plans last year.
Way back when Novartis invested in personalised CAR-T cancer treatments being developed at the University of Pennsylvania, analysts pondered the tricky question: How can pharma companies profit from curing patients?
The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB).